Lymphoma, Follicular: all 964 studies

Page 4 of 10. Open to participants first (242), then studies with results posted, then the rest; newest registration first within each.

• A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedNCT03105336Phase 2Results posted
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaCompletedNCT03010358Phase 1/2Results posted
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaCompletedNCT02956382Phase 1/2Results posted
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaCompletedNCT02947347Phase 3Results posted
• TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedNCT02927964Phase 1/2Results posted
• Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular LymphomaCompletedNCT02871219Phase 2Results posted
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantCompletedNCT02869633Phase 2Results posted
• Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaTerminatedNCT02855359Phase 2Results posted
• A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedNCT02809053Phase 3Results posted
• Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantActive, not recruitingNCT02797470Phase 1/2Results posted
• A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02729896Phase 1/2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
• A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaCompletedNCT02631577Phase 1/2Results posted
• A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) ParticipantsTerminatedNCT02624986Phase 1/2Results posted
• A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02611323Phase 1/2Results posted
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
• Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 2Results posted
• A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular LymphomaCompletedNCT02569996Phase 3Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results posted
• Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma ParticipantsCompletedNCT02536664Results posted
• Dose Optimization Study of Idelalisib in Follicular LymphomaTerminatedNCT02536300Phase 3Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)TerminatedNCT02501473Phase 1/2Results posted
• A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular LymphomaCompletedNCT02472756Results posted
• Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1CompletedNCT02461290Results posted
• Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaActive, not recruitingNCT02446457Phase 2Results posted
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
• BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular LymphomaTerminatedNCT02417129Phase 3Results posted
• An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaTerminatedNCT02413489Phase 2Results posted
• A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedNCT02391545Phase 1/2Results posted
• QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabTerminatedNCT02384954Phase 1/2Results posted
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
• Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)CompletedNCT02316613Results posted
• Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaTerminatedNCT02282358Phase 1/2Results posted
• A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)CompletedNCT02278796Phase 2Results posted
• To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular LymphomaCompletedNCT02260804Phase 3Results posted
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaTerminatedNCT02258529Phase 2Results posted
• Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedNCT02257242Phase 1Results posted
• A Phase I/II Study of Intratumoral Injection of SD-101CompletedNCT02254772Phase 1/2Results posted
• Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasCompletedNCT02213913Phase 1/2Results posted
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)CompletedNCT02213263Phase 3Results posted
• Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
• Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaTerminatedNCT02204982Phase 3Results posted
• A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)CompletedNCT02187861Phase 2Results posted
• Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02180711Phase 1/2Results posted
• To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With RituxanCompletedNCT02162771Phase 3Results posted
• A Phase II Study of Doxycycline in Relapsed NHLTerminatedNCT02086591Phase 2Results posted
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
• Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)CompletedNCT02038946Phase 2Results posted
• Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01995669Phase 1/2Results posted
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedNCT01950273Phase 1Results posted
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
• Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular LymphomaCompletedNCT01939899Phase 2Results posted
• Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLCompletedNCT01897571Phase 1/2Results posted
• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)CompletedNCT01889069Phase 3Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT01849263Phase 2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aCompletedNCT01724021Phase 3Results posted
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHLCompletedNCT01693614Phase 2Results posted
• Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaCompletedNCT01682044Phase 2Results posted
• A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant DiseaseCompletedNCT01680991Phase 1Results posted
• Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
• Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)TerminatedNCT01662102Phase 3Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3Results posted
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaCompletedNCT01476787Phase 3Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
• GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)CompletedNCT01419665Phase 3Results posted
• Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
• Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell LymphomaTerminatedNCT01397591Phase 2Results posted
• Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular LymphomaTerminatedNCT01389076Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaCompletedNCT01381692Phase 1/2Results posted
• Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)TerminatedNCT01370694Phase 1Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedNCT01321541Phase 3Results posted
• Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin LymphomaActive, not recruitingNCT01318317Phase 1/2Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaCompletedNCT01306643Phase 1/2Results posted
• Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasCompletedNCT01282424Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular LymphomaCompletedNCT01234766Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted

← Lymphoma, Follicular overview